DOD Amyotrophic Lateral Sclerosis, Clinical Outcomes and Biomarkers Award

The Department of Defense's Amyotrophic Lateral Sclerosis Research Program (ALSRP) invites applications for the Clinical Outcomes and Biomarkers Award (COBA) for fiscal year 2025. This funding opportunity aims to support research focused on developing and validating clinical outcomes and biomarkers to enhance ALS clinical trials, targeting specific therapies or genetic mutations without needing broad applicability to all patients. Approximately $6.2 million is allocated to fund around five awards, with a maximum budget of $750,000 for a period of up to three years. Eligible applicants include both domestic and foreign organizations, academic institutions, and non-profit entities. Independent investigators at all career levels can serve as Principal Investigators. The application process includes a two-step submission: a pre-application due by June 6, 2025, and a full application due by August 27, 2025. Key focus areas include identifying clinical biomarkers for ALS and developing outcome measures that could impact clinical trial success. The proposal must incorporate community collaboration, emphasizing the involvement of patients and caregivers to ensure research relevance. Applications should detail plans for data sharing and resource utilization, aligning with regulatory considerations for ALS therapy development. The review process comprises preliminary screenings and comprehensive assessments evaluating scientific merit and relevance to the program’s objectives.